Eisai braced for reimbursement challenges ahead of Russia entry
This article was originally published in Scrip
Executive Summary
Eisai has announced plans to enter the Russian healthcare market by establishing a new Moscow-based sales and marketing operation. The timing of the announcement coincides with the anticipated launch of the company's breast cancer treatment, Halaven (eribulin), in the region in the second quarter.